D3 Technologies, a subsidiary of Renishaw, was honoured with a spin-out recognition award at the recent University of Strathclyde Enterprise Awards
The award recognised D3 for its work on trace detection used in drug development, forensic science and medical diagnostics.
A successful spin-out from the University of Strathclyde, D3 Technologies attracted the interest of Renishaw, which acquired a 75% interest in the newly formed company in July 2007.
Part of the investment was then used by D3 to purchase the business and assets of the analytical business unit (ABU) operated by Mesophotonics, a spin-out from the University of Southampton.
The ABU develops and manufactures substrates used in Sers applications.
The Strathclyde Enterprise Awards aim to give recognition to some of Scotland's smartest and most inventive businesses which have been supported by the University's enterprise network.
At the awards ceremony hosted by STV presenter Debi Edward, nine awards were granted for projects as diverse as drug development, website creation, environmentally-sound kettles and coffee cups with adaptable handles.
Speaking about his company's award, Professor Ewen Smith, D3's CEO, said: "We are delighted to receive this award which recognises the work of all our team in developing improved DNA-based diagnostic tests to detect diseases, or the genetic predisposition to diseases.
"I would also like to thank the University of Strathclyde and Renishaw for their support and belief in the work of D3".
David McBeth, director of research and innovation at Strathclyde, said: "The awards have been presented to give credit to the innovative, creative companies the University has advised and supported and to inspire others to follow their example."
